CML in pregnancy outcome following therapy
| CML . | First trimester . | Outcome . | Second/third trimester . | Outcome . |
|---|---|---|---|---|
| HC | ||||
| N = 566 ; continued throughout pregnancy | Normal infant, n = 4; eclampsia at 26 wk; stillbirth, n = 1 | |||
| Imatinib | ||||
| N = 180 (outcome, n = 125)70 | 70% | SA, n = 4 | n = 18 (26%); imatinib throughout pregnancy | SA, n = 18; TOP, n = 35 (CA, n = 3); total CA, n = 12; normal infants, n = 63 |
| N = 1071 | SA, n = 2 | |||
| N = 21772 | Pregnancy to term, n = 171 (n = 109 FU; UNK = 62); SA, n = 24; CA, n = 9; LBW, n = 2; IUFD, n = 1 | |||
| Imatinib continued throughout pregnancy, n = 273 | Pregnancy to term; LBW, n = 2 | |||
| 2G-TKI | ||||
| Dasatinib, N = 4 | n = 176 | Fetal hydrops and cytopenia | ||
| n = 1 (5/40 wk)77 | Normal pregnancy, induction of labor | |||
| n = 1(4/40 wk)78 | Normal pregnancy, LSCS at 33 wk | |||
| n = 1 (6/40 wk)79 | Normal pregnancy, SVD at 37/40 wk | |||
| Dasatinib,74 N = 8 | TOP, n = 3 SA, n = 2 (8/40 and 9/40) Deliveries, n = 3; normal infant, n = 1 | |||
| LSCS at 7 mo, “small for dates” | ||||
| Normal pregnancy at 21 wk, outcome unknown | ||||
| Nilotinib,75 N = 1 | 8/40 wk | Normal pregnancy LSCS at 33 wk | ||
| CML . | First trimester . | Outcome . | Second/third trimester . | Outcome . |
|---|---|---|---|---|
| HC | ||||
| N = 566 ; continued throughout pregnancy | Normal infant, n = 4; eclampsia at 26 wk; stillbirth, n = 1 | |||
| Imatinib | ||||
| N = 180 (outcome, n = 125)70 | 70% | SA, n = 4 | n = 18 (26%); imatinib throughout pregnancy | SA, n = 18; TOP, n = 35 (CA, n = 3); total CA, n = 12; normal infants, n = 63 |
| N = 1071 | SA, n = 2 | |||
| N = 21772 | Pregnancy to term, n = 171 (n = 109 FU; UNK = 62); SA, n = 24; CA, n = 9; LBW, n = 2; IUFD, n = 1 | |||
| Imatinib continued throughout pregnancy, n = 273 | Pregnancy to term; LBW, n = 2 | |||
| 2G-TKI | ||||
| Dasatinib, N = 4 | n = 176 | Fetal hydrops and cytopenia | ||
| n = 1 (5/40 wk)77 | Normal pregnancy, induction of labor | |||
| n = 1(4/40 wk)78 | Normal pregnancy, LSCS at 33 wk | |||
| n = 1 (6/40 wk)79 | Normal pregnancy, SVD at 37/40 wk | |||
| Dasatinib,74 N = 8 | TOP, n = 3 SA, n = 2 (8/40 and 9/40) Deliveries, n = 3; normal infant, n = 1 | |||
| LSCS at 7 mo, “small for dates” | ||||
| Normal pregnancy at 21 wk, outcome unknown | ||||
| Nilotinib,75 N = 1 | 8/40 wk | Normal pregnancy LSCS at 33 wk | ||
LBW, low birth weight; UNK, unknown outcome. Other abbreviations are explained in Table 1.